Alkermes, Inc. Company Profile Complimentary D&B Business Overview on over 38 million companies with Free Registration!

Alkermes, Inc.

64 Sidney Street
Cambridge, MA 02139-4136
United States
Tel: 1/617/494-0171
URL: http://www.alkermes.com
Primary Symbols & Exchanges:
ALKS - NASDAQ
Primary Industry:
Pharmaceutical
SIC Industry Code:
Mergers & Acquisitions:
Alkermes, Inc. Mergers and Acquisitions
Thomson Financial Business Description:
The Group's principal activity is that of a biotechnology company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes of major diseases. It has two commercial products namely: RISPERDAL(R) CONSTA(R): The only long-acting atypical antipsychotic medication approved for use in schizophrenia and is marketed worldwide by Janssen-Cilag (Janssen), a wholly owned division of Johnson & Johnson. VIVITROL(R) (naltrexone for extended-release injectable suspension) is the only monthly injectable medication approved for the treatment of alcohol dependence and is marketed in the United States primarily by Cephalon Inc. In addition, the Group has a pipeline of extended-release injectable products and pulmonary products based on its proprietary technology and expertise. The Group partners with many of the world's premier pharmaceutical companies and also works independently to create novel, proprietary drug products.
Alacra Alerts: Alkermes, Inc. RSS Feed  Subscribe with My Yahoo!
Receive alerts on the latest reports on Alkermes, Inc.

Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.

Premium Content Results:







Search for more premium content on Alkermes, Inc.
  about us contact us public company index private company index pcan widget your privacy rights terms & conditions